Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

847 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Warren RB, Pavlovsky L, Costanzo A, Bukhalo M, Korman NJ, Huang YH, Kokolakis G, Pinter A, Ibrahim N, Zheng Y, Drogaris L, Stakias V, Soliman AM, Rubant S, Thaçi D. Warren RB, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 Dec;14(12):3273-3290. doi: 10.1007/s13555-024-01292-z. Epub 2024 Nov 8. Dermatol Ther (Heidelb). 2024. PMID: 39516454 Free PMC article.
Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study.
Valenti M, Gargiulo L, Ibba L, Cortese A, Toso F, Orsini D, Lora V, Frascione P, Sena P, Carugno A, Assorgi C, Costanzo A, Narcisi A. Valenti M, et al. Among authors: costanzo a. J Dermatol. 2024 Jun;51(6):839-843. doi: 10.1111/1346-8138.17115. Epub 2024 Jan 31. J Dermatol. 2024. PMID: 38292002 Free PMC article.
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO.
Riedl E, Pinter A, Zaheri S, Costanzo A, Brnabic A, Konicek B, McKenzie R, Lampropoulou A, Rayes ME, Haustrup N, Schuster C. Riedl E, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 May;14(5):1327-1335. doi: 10.1007/s13555-024-01150-y. Epub 2024 Apr 22. Dermatol Ther (Heidelb). 2024. PMID: 38649673 Free PMC article.
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Valenti M, Gargiulo L, Ibba L, Malagoli P, Amoruso F, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Travaglini M, Costanzo A, Narcisi A. Valenti M, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 Jun;14(6):1649-1657. doi: 10.1007/s13555-024-01182-4. Epub 2024 May 15. Dermatol Ther (Heidelb). 2024. PMID: 38748344 Free PMC article.
Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A, Costanzo A, Khattri S, Smith SD, Carrascosa JM, Tada Y, Riedl E, Reich A, Brnabic A, Haustrup N, Lampropoulou A, Lipkovich I, Kadziola Z, Paul C, Schuster C. Pinter A, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 Jun;14(6):1495-1496. doi: 10.1007/s13555-024-01105-3. Dermatol Ther (Heidelb). 2024. PMID: 38814435 Free PMC article. No abstract available.
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C. Puig L, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 Sep;14(9):2539-2558. doi: 10.1007/s13555-024-01245-6. Epub 2024 Aug 17. Dermatol Ther (Heidelb). 2024. PMID: 39153060 Free PMC article.
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.
Malagoli P, Dapavo P, Amerio P, Atzori L, Balato A, Bardazzi F, Bianchi L, Cattaneo A, Chiricozzi A, Congedo M, Fargnoli MC, Giofrè C, Gisondi P, Guarneri C, Lembo S, Loconsole F, Mazzocchetti G, Mercuri SR, Morrone P, Offidani AM, Palazzo G, Parodi A, Pellacani G, Piaserico S, Potenza C, Prignano F, Romanelli M, Savoia P, Stingeni L, Travaglini M, Trovato E, Venturini M, Zichichi L, Costanzo A. Malagoli P, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 Oct;14(10):2739-2757. doi: 10.1007/s13555-024-01255-4. Epub 2024 Sep 24. Dermatol Ther (Heidelb). 2024. PMID: 39316358 Free PMC article. Review.
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).
Valenti M, Ibba L, Cascio Ingurgio R, Malagoli P, Carugno A, Campoli M, Carrera CG, Gaiani FM, Strippoli D, Mola F, Marzano AV, Zerbinati N, Minuti A, Costanzo A, Narcisi A. Valenti M, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 Nov;14(11):2987-2997. doi: 10.1007/s13555-024-01270-5. Epub 2024 Oct 13. Dermatol Ther (Heidelb). 2024. PMID: 39397217 Free PMC article.
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).
Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Silverberg JI, et al. Among authors: costanzo a. Br J Dermatol. 2024 Dec 23;192(1):36-45. doi: 10.1093/bjd/ljae404. Br J Dermatol. 2024. PMID: 39438067 Clinical Trial.
847 results